Literature DB >> 9153447

A beneficial effect of oxandrolone in the treatment of Duchenne muscular dystrophy: a pilot study.

G Fenichel1, A Pestronk, J Florence, V Robison, V Hemelt.   

Abstract

We treated 10 boys with Duchenne muscular dystrophy with oxandrolone, an anabolic steroid, for 3 months. The mean of the changes in the average muscle score was an improvement of 0.315 +/- 0.097. The expected mean change in muscle score after 3 months from natural history data is a loss of 0.1. The difference of 0.415 between the actual and expected values is significant at p < 0.01. This preliminary evidence suggests that oxandrolone treatment may provide a degree of functional benefit for children with Duchenne muscular dystrophy that is similar to that after prednisone administration.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9153447     DOI: 10.1212/wnl.48.5.1225

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  Ventilation during air breathing and in response to hypercapnia in 5 and 16 month-old mdx and C57 mice.

Authors:  Jerome Gayraud; Stefan Matecki; Karim Hnia; Dominique Mornet; Christian Prefaut; Jacques Mercier; Alain Michel; Michele Ramonatxo
Journal:  J Muscle Res Cell Motil       Date:  2007-04-13       Impact factor: 2.698

2.  Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy.

Authors:  D M Escolar; L P Hache; P R Clemens; A Cnaan; C M McDonald; V Viswanathan; A J Kornberg; T E Bertorini; Y Nevo; T Lotze; A Pestronk; M M Ryan; E Monasterio; J W Day; A Zimmerman; A Arrieta; E Henricson; J Mayhew; J Florence; F Hu; A M Connolly
Journal:  Neurology       Date:  2011-07-13       Impact factor: 9.910

Review 3.  Pharmacologic and genetic therapy for childhood muscular dystrophies.

Authors:  D M Escolar; C G Scacheri
Journal:  Curr Neurol Neurosci Rep       Date:  2001-03       Impact factor: 5.081

4.  Making fast-twitch dystrophic muscles bigger protects them from contraction injury and attenuates the dystrophic pathology.

Authors:  Stefan M Gehrig; René Koopman; Timur Naim; Clarissa Tjoakarfa; Gordon S Lynch
Journal:  Am J Pathol       Date:  2009-12-03       Impact factor: 4.307

Review 5.  The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety.

Authors:  Rhonda Orr; Maria Fiatarone Singh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 6.  Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis.

Authors:  Nermina Ferizovic; Jessica Summers; Igor Beitia Ortiz de Zárate; Christian Werner; Joel Jiang; Erik Landfeldt; Katharina Buesch
Journal:  PLoS One       Date:  2022-03-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.